Ebola Spreads to Kenya as Lancet Commission Maps Seventeen Catastrophic Global Threats

Six stories define this week in global health: the world's largest recorded Bundibugyo Ebola outbreak crossing an international border, a landmark commission charting the health threats that could define the century, two significant FDA approvals in oncology and psychiatry, a promising early gene therapy result, and a yellow fever emergency in West Africa.

Ebola Bundibugyo Outbreak Crosses into Kenya as DRC Toll Surpasses 8,700 Cases

The Ebola epidemic caused by Bundibugyo virus in the Democratic Republic of the Congo has passed 8,728 confirmed cases and 4,205 confirmed deaths as of October 6, according to the WHO's latest Disease Outbreak News. The outbreak — the largest ever recorded for this strain — has now spread to 64 health zones across seven provinces, with Ituri remaining the worst-affected province and North Kivu's share of new infections growing. The WHO has assessed risk in the DRC as very high, in bordering countries as high, and globally as low.

This week brought two alarming developments. Al Jazeera reported that Kenya confirmed its first imported case — a Kenyan citizen who had been living in the DRC — who died on October 5. Kenya's Ministry of Health has activated a rapid contact-tracing response. Separately, the WHO confirmed first-ever cases in Alimbongo health zone in North Kivu province, indicating that the outbreak's geographic reach is still expanding.

A critical constraint shapes the entire response: unlike the Sudan or Zaire strains of Ebola virus disease, for which licensed vaccines now exist, no approved vaccine or specific antiviral has been validated against Bundibugyo virus. The WHO declared a public health emergency of international concern (PHEIC) on May 17, 2026. Anyone planning travel to eastern DRC or the Great Lakes region should consult current WHO and national health authority guidance well in advance of departure.

Lancet Commission Identifies Seventeen Catastrophic Threats to Human Health This Century

A landmark report published in The Lancet on October 10, 2026 — the Lancet Commission on 21st Century Global Threats to Health — has catalogued 17 threats capable of causing mass death or civilisational disruption between now and 2100. Co-chaired by IHME director Christopher Murray and UNFPA executive director Natalia Kanem, the commission analysed data across 204 countries and modelled best-case and worst-case trajectories using disability-adjusted life years (DALYs) as a common measure of harm.

The list includes climate change, air pollution, antimicrobial resistance, obesity, tobacco, alcohol, pandemic preparedness gaps, conflict, and emerging pathogens — all well-established concerns. What marks this report as significant is its explicit identification of two threats as potentially extinction-level: the malicious use of artificial intelligence and nuclear conflict. Both are characterised by the possibility of outcomes with no recovery pathway.

The commission also proposes a Lancet Monitor of 21st Century Global Threats to Health — a standing surveillance mechanism to track how each threat evolves over time. A central conclusion is that the burden of these risks will not be distributed equally: populations with low incomes and already-marginalised communities stand to bear a disproportionate share of harm from every threat on the list.

For clinicians, policymakers, and health planners in Cyprus and the eastern Mediterranean, the report functions as a framework document. Antimicrobial resistance, climate-related health impacts, and pandemic preparedness gaps are all named threats with direct and immediate regional relevance.

FDA Approves Tucatinib Combination as First-Line Maintenance for HER2-Positive Metastatic Breast Cancer

On October 7, the FDA approved tucatinib (Tukysa, Pfizer) in combination with trastuzumab and pertuzumab as maintenance therapy for adults with HER2-positive unresectable locally advanced or metastatic breast cancer whose disease has not progressed after first-line induction treatment. The FDA's announcement marks the first approved maintenance strategy specifically designed for this setting.

The approval rests on HER2CLIMB-05, a randomised, double-blind, placebo-controlled Phase 3 trial in 654 patients. Adding tucatinib to the standard doublet reduced the risk of disease progression or death by approximately 36%, with a median progression-free survival of 24.9 months compared to 16.3 months in the placebo arm — a gain of more than eight months. Overall survival data are not yet mature and will be reported as follow-up continues. The label includes a boxed warning for hepatotoxicity; liver function monitoring during treatment is required. Management protocols for diarrhoea, a common side effect of the drug class, are also part of standard guidance.

HER2-positive breast cancer accounts for roughly 15–20 percent of all breast cancer diagnoses globally and has historically been associated with a more aggressive clinical course before the introduction of anti-HER2 targeted therapies. For patients whose metastatic disease has responded to first-line induction, this approval offers a structured approach to extending that response.

Once-Monthly Olanzapine Injection Approved for Schizophrenia, Without Post-Dose Observation Requirement

The FDA approved Teva's Weltruza (olanzapine subcutaneous extended-release injection) on October 9 as a once-monthly long-acting injectable for adults with schizophrenia — the first formulation of long-acting olanzapine that does not require post-injection monitoring. The approval rests on the Phase 3 SOLARIS trial (675 participants), which demonstrated improvements across standard symptom severity scores, illness rating, and personal and social functioning at three monthly dose levels, according to AJMC's reporting.

The clinical significance of the monitoring question is practical. Earlier long-acting olanzapine products (Zyprexa Relprevv) carry a REMS programme requiring three hours of post-dose observation in a healthcare facility due to a risk of post-injection delirium/sedation syndrome — a requirement that has limited their uptake in settings without adequate infrastructure. Weltruza, using a subcutaneous delivery system developed with MedIncell, generates a distinct pharmacokinetic profile that, in the SOLARIS trial data, did not produce this pattern. No loading dose is required, and Teva expects the product to be available in the United States within weeks.

Schizophrenia affects approximately 24 million people globally. Long-acting injectables are among the best-evidenced strategies for maintaining adherence and reducing the relapse-hospitalisation cycle. A formulation that removes the post-dose observation burden could widen access in community mental health settings, including in the Mediterranean region where outpatient psychiatric infrastructure varies considerably by country.

Phase 1/2 NEJM Trial Finds Gene Therapy Improves Light Sensitivity in Some Patients with Inherited Blindness

An open-label Phase 1/2 trial published in the New England Journal of Medicine on October 8 (NEJMoa2602215) reports encouraging but explicitly exploratory results for GS030, an optogenetic gene therapy for advanced retinitis pigmentosa. Conducted by Gensight Biologics and the Quinze-Vingts National Hospital in Paris, the trial enrolled 10 participants with advanced hereditary retinal dystrophy causing near-total blindness. Its primary endpoint was safety — evaluating a single intravitreal injection of an AAV vector that delivers ChrimsonR, a light-sensitive protein, to surviving retinal ganglion cells, used in combination with specialised light-stimulating goggles.

The safety profile was acceptable, with no serious adverse events attributed to the therapy. On exploratory measures, 6 of the 10 participants showed clinically meaningful improvements in light sensitivity on full-field stimulus threshold testing. Of the 8 who completed behavioural assessments, 4 demonstrated positive changes in their ability to perform real-world visual tasks while using the device. EEG evidence in a subset provided objective support suggesting genuine visual cortex activation.

These findings must be understood in context: this is a 10-patient, Phase 1/2 safety trial. The study was not powered or designed to establish efficacy, and results cannot yet generalise to the wider population of people living with retinitis pigmentosa. Nonetheless, the approach — bypassing degenerated photoreceptors entirely to redirect light sensitivity to surviving cells further along the visual pathway — represents a scientifically rigorous avenue for restoring partial vision where no other treatment currently exists. Larger, controlled trials will be needed before efficacy conclusions can be drawn.

Ghana Declares Yellow Fever Outbreak in Upper West Region; Emergency Vaccination Campaign Under Way

Ghana's Ministry of Health declared a yellow fever outbreak in the Upper West Region on October 9, following laboratory confirmation of three fatal cases at a WHO-accredited reference laboratory. The Ghana News Agency reported that rapid response teams have been deployed to the affected districts — Wa West, Sissala West, and Sissala East — and that an emergency vaccination campaign targeting people aged nine months to 60 years is being prepared for immediate rollout. The declaration was made in coordination with the WHO.

The outbreak does not appear to have emerged from nothing: between June and September 2026, approximately 450 suspected yellow fever cases were reported across Ghana, and in the Upper West Region alone, 74 to 88 suspected cases and seven unconfirmed deaths preceded the formal declaration. The Health Minister has stated that the situation is under control and has urged the public to rely on official channels for information.

Yellow fever does not circulate in Cyprus or the wider eastern Mediterranean. However, the disease is endemic in tropical Africa and parts of South America, and proof of vaccination (via the International Certificate of Vaccination — the yellow card) is a formal entry requirement for many sub-Saharan African and South American countries. Travellers from the region planning visits to at-risk destinations should ensure they are vaccinated at least ten days before departure and carry their vaccination certificate.

---

This article is written for informational and journalistic purposes only and does not constitute medical advice. Always consult a qualified clinician before making any change to your treatment, vaccination schedule, or medications.